Pacritinib Administration via Nasogastric Tube and Hazardous Drug Classification
Pacritinib is NOT considered a hazardous drug and CAN be administered via nasogastric (NG) tube with appropriate precautions.
Hazardous Drug Status
Pacritinib does not appear on standard hazardous drug lists. The available evidence does not classify it as hazardous requiring special handling precautions beyond standard pharmaceutical practices. Unlike cytotoxic chemotherapy agents, pacritinib is an oral JAK2/IRAK1 inhibitor that does not require the specialized handling protocols reserved for hazardous medications 1, 2.
NG Tube Administration
Pacritinib tablets can be crushed and administered via NG tube, following established guidelines for enteral medication administration 3, 4, 3.
Administration Protocol:
- Crush the tablet and suspend in water (approximately 30-60 mL)
- Administer immediately through the gastric tube
- Flush the tube with at least 30 mL of water before and after administration to prevent tube occlusion 3, 4
- Use appropriate ENFit syringes to avoid misconnection errors 3, 4
- Avoid shaking low-dose ENFit syringes to remove drug moats, as this can affect dosing accuracy 3
Critical Considerations:
Consult a pharmacist before crushing and administering pacritinib via NG tube, as this represents off-label use not specifically addressed in the product labeling 3, 4, 3. The pharmacist can:
- Confirm drug stability when crushed
- Verify appropriate dosing accuracy
- Assess potential drug-tube interactions
- Suggest alternative formulations if available
Absorption site matters: Ensure the NG tube terminates in the stomach, not distal to it, as pacritinib absorption may be reduced if delivered beyond the gastric environment (similar to other oral kinase inhibitors) 5.
Common Pitfalls to Avoid:
- Do not crush without pharmacist consultation - crushing medicines should be avoided whenever possible due to risks of exposure and dosing inaccuracies 3, 4
- Do not administer distal to the stomach - bioavailability may be compromised 5
- Do not skip tube flushing - pacritinib as a solid dosage form may increase risk of tube occlusion 3
- Monitor for tube blockage - solid dosage forms have higher incidence of tube occlusions, particularly with nasogastric and silicone PEG tubes 3, 4
Safety Monitoring:
Given pacritinib's gastrointestinal side effect profile (diarrhea in 69%, nausea in 49% of patients) 6, monitor closely for:
- Increased GI symptoms after NG administration
- Adequate drug absorption (consider checking drug levels if available)
- Tube patency and function
The responsibility for any adverse events from off-label crushing and NG administration rests with the prescriber, pharmacist, and administering personnel 3, 4.